Skip to main content

Advertisement

Table 1 The characteristics of MPNs in Malaysia

From: The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia

No Characteristics Total MPNs JAK2 V617F positivea JAK2 V617F negativea p-value
N (%) n (%) n (%)
1. Total patients, n 1010 644 222  
2. Age at diagnosis, year
   Mean (sd) 54.2 (14.88) 55.9 (13.39) 49.1 (16.59) < 0.001
   95% CI for population mean 53.32, 55.16 54.90, 56.97 46.87, 51.26  
3. Sex
   Female 488 (48.3) 317 (49.2) 99 (44.6) 0.234
   Male 522 (51.7) 327 (50.8) 123 (55.4)  
4. Ethnic groupsb
   Malay 447 (44.2) 310 (48.1) 84 (37.8) < 0.001
   Chinese 412 (40.8) 253 (39.3) 104 (46.8)  
   Indian 65 (6.4) 32 (5.0) 24 (10.8)  
   Native—Sabah 42 (4.2) 22 (3.4) 5 (2.3)  
   Native—Sarawak 19 (1.9) 13 (2.0) 0 (0)  
   Others 25 (2.5) 14 (2.2) 5 (2.3)  
5. MPN sub-types
   ET 408 (40.4) 232 (36.0) 123 (55.4) < 0.001
   PV 385 (38.1) 300 (46.6) 49 (22.1)  
   PMF 93 (9.2) 58 (9.0) 12 (5.4)  
   HES 31 (3.1) 0 (0) 22 (9.9)  
   MPN-U 80 (7.9) 48 (7.4) 11 (5.0)  
   Others 5 (0.5) 1 (0.2) 2 (0.9)  
   Not documented/missing 8 (0.8) 5 (0.8) 3 (1.3)  
6. Splenomegaly
   Yes 325 (32.2) 237 (36.8) 35 (15.8) < 0.001
   No 680 (67.3) 405 (62.9) 186 (83.8)  
   Not documented/missing 5 (0.5) 2 (0.3) 1 (0.4)  
7. Presenting vasomotor symptomsc
   Yes 218 (21.6) 154 (23.9) 36 (16.2) 0.015
   No 780 (77.2) 482 (74.8) 185 (83.3)  
   Not documented/missing 12 (1.2) 8 (1.3) 1 (0.5)  
8. Presenting arterial thrombosisd
   Yes 209 (20.7) 149 (23.1) 28 (12.6) < 0.001
   No 792 (78.4) 492 (76.4) 193 (86.9)  
   Not documented/missing 9 (0.9) 3 (0.5) 1 (0.5)  
9. Presenting venous thrombosise
   Yes 35 (3.5) 28 (4.4) 4 (1.8) 0.082
   No 967 (95.7) 612 (95.0) 217 (97.7)  
   Not documented/missing 8 (0.8) 4 (0.6) 1 (0.5)  
10. Presenting bleedingf
   Yes 67 (6.6) 40 (6.2) 14 (6.3) 0.956
   No 936 (92.7) 602 (93.5) 207 (93.2)  
   Not documented/missing 7 (0.7) 2 (0.3) 1 (0.5)  
11. Incidental finding
   During medical attention for unrelated condition 494 (48.9) 324 (50.3) 109 (49.1) 0.324
   Health screening 118 (11.7) 69 (10.7) 32 (14.4)  
   No 379 (37.5) 242 (37.6) 78 (35.1)  
   Not documented/missing 19 (1.9) 9 (1.4) 3 (1.4)  
12. BM fibrosis
   Grade 0 157 (15.5) 94 (14.6) 38 (17.1) 0.202
   Grade 1 86 (8.5) 60 (9.3) 14 (6.3)  
   Grade 2 48 (4.7) 33 (5.1) 12 (5.4)  
   Grade 3 52 (5.1) 40 (6.2) 6 (2.7)  
   Grade 4 21 (2.1) 12 (1.9) 4 (1.8)  
   Suboptimal sample 83 (8.2) 50 (7.7) 24 (10.8)  
   Not done 544 (53.9) 345 (53.6) 121 (54.5)  
   Not documented/missing 19 (2.0) 10 (1.5) 3 (1.4)  
  1. aJAK2 V617F mutation result was not reported for 144 patients
  2. bNatives from Sabah and Sarawak, and others are grouped together for Chi square test as the expected count must be at least 2
  3. cPresenting vasomotor symptoms include headache, transient neurologic or ocular symptoms, distal paraesthesias, erythromelalgia, and others
  4. dPresenting arterial thrombosis includes stroke/transient ischemic attack (TIA), acute coronary syndrome, digital gangrene, retinal artery occlusion, mesenteric artery thrombosis, and others
  5. ePresenting venous thrombosis includes hepatic or portal vein thrombosis, deep vein thrombosis (DVT), retinal vein thrombosis, sagittal sinus thrombosis, pulmonary embolism (PE), and others
  6. fPresenting bleedings include gastro intestinal tract (GIT) unspecified, post-surgical bleed, mucocutaneous, and others